Novavax, Inc.
NVAX
$9.06
-$0.29-3.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -79.07% | 66.61% | -16.64% | -42.42% | 610.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -79.07% | 66.61% | -16.64% | -42.42% | 610.30% |
| Cost of Revenue | 25.05% | -24.04% | -22.34% | -42.43% | -40.18% |
| Gross Profit | -95.30% | 112.33% | 32.15% | -42.41% | 1,122.01% |
| SG&A Expenses | -38.89% | -128.05% | -42.92% | -53.23% | -26.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.73% | -40.97% | -30.10% | -47.29% | -35.23% |
| Operating Income | -101.94% | 116.69% | 38.85% | -34.81% | 471.95% |
| Income Before Tax | -101.64% | 124.33% | -65.97% | -34.71% | 457.80% |
| Income Tax Expenses | -17.92% | -94.95% | 36.34% | -57.10% | -46.95% |
| Earnings from Continuing Operations | -101.83% | 121.63% | -66.84% | -34.41% | 451.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.83% | 121.63% | -66.84% | -34.41% | 451.51% |
| EBIT | -101.94% | 116.69% | 38.85% | -34.81% | 471.95% |
| EBITDA | -101.33% | 123.07% | 37.84% | -34.63% | 514.23% |
| EPS Basic | -101.80% | 121.32% | -64.47% | -39.93% | 405.37% |
| Normalized Basic EPS | -100.59% | 124.18% | 36.83% | -38.06% | 424.82% |
| EPS Diluted | -101.98% | 121.31% | -64.47% | -38.09% | 378.28% |
| Normalized Diluted EPS | -100.65% | 123.79% | 36.83% | -36.71% | 394.50% |
| Average Basic Shares Outstanding | 1.38% | 1.43% | 1.44% | 9.19% | 15.10% |
| Average Diluted Shares Outstanding | -8.08% | 3.08% | 1.44% | 6.85% | 26.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |